TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT01954992: Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

Sponsor: Eleison Pharmaceuticals LLC. · Phase: PHASE3 · Area: ONCOLOGY · Target Enrollment: 480 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$20,993,280

Rescue Site Savings

+$13,842,444

Unlock Full NCT01954992 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT01954992 Rescue Dossier →